The hemostatic tool

 

The proposal relates to hemostatic medium containing calcium alginate as a basis, plant extracts,-aminocaproic acid to stop the capillary and mixed hemorrhage in traumatic lesions of the skin and muscle tissue in surgical practice. The tool has an effective hemostatic properties and the absence of allergic reactions. table 1.

The invention relates to medical pharmacology, namely organic geostatical used to stop the capillary and mixed hemorrhage in traumatic lesions of the skin and muscle tissues, as well as in surgical practice.

Analogues of hemostatic drugs are "Spongostan", "Coalgan (France) /1/, "Hemal" (USA) /2/, "Allstat" (France), domestic agents hemostatic sponge and gelatin /3/. The analogs may include fibrin sealants, glues, pastes, such as fibrin glue for U.S. patent 5773418, in which the adjuvant is used as antibiotic, antitumor agent, an antagonist of histamine H2, fibronectin and inhibitor of fibrinolysis, fibrin glue contains a polymer fibrin /4/.

And the preparations are complex compositions of drugs, the expensive part.

The closest in technical essence and the achieved result is a domestic product "Zhelplastan" /6/.

"Zhelplastan" contains blood plasma of cattle, gelatin and the antibiotic kanamycin sulfate. "Zhelplastan has a pronounced hemostatic effect, however, of the active substance components of the drug during the technological cycle are deactivated, the blood plasma of cattle entered in its composition in the finished dosage form, on the hemostatic properties of the drug has virtually no effect. Antibacterial component is not valid. The hemostatic properties of the drug are mainly determined by gelatin powder, which is structured in a certain way during the process, but is practically insoluble, which impairs its adhesive properties (especially in the first application).

The purpose of this invention is to provide a powdery medicine based on herbal and synthetic components with highly effective hemostatic properties and absence of allergic reactions.

This goal is achieved by the fact that the hemostatic agent contains as a about what you Epsilon-aminocaproic acid, in a ratio of components, wt.%: Alginate calcium - 50-80 Phytoextracts - 15-30 Epsilon-aminocaproic acid - 5-20 calcium Alginate is used as the basis of the preparation and role of the matrix in the formation of thrombi. To improve the hemostatic properties of the drug add the extract of oak bark, and to improve wound healing, anti-inflammatory, antiseptic properties of the herbal extracts.

Upon contact of the drug with bleeding particles of calcium alginate close the wound surface, taking its shape without causing trauma to the surrounding tissue. They reinforce normal thrombus formation, acting as a matrix around which are formed blood clots and recovered platelets. Calcium ions polysaccharide base stimulates the process of thrombus formation. Due to tannins, covering particle basis, the strengthening of blood clots and their adgezirovannah to the wound surface, and each other. Having a large surface area and good adsorption properties, powder foundations quickly soaked bleeding. This increases the concentration of tambourissa substances on their surface. Castilletti, and provides a prolonged effect.

After application of the drug on the surface of the wound its active ingredients are dissolved in the flowing blood and provide hemostatic and wound healing effect.

So, tanning phytoextracts direct cause coagulation of plasma proteins that provides rapid thrombus formation and good adhesion of the particles of the basics. They cause compaction of the surface layer of tissue on the wound surface reduction of permeability due to non-specific physico-chemical changes of colloids cells and extracellular fluid. Thus forming a dense protective film, which protects the tissue from exposure to irritating substances, reducing pain, contributing to the narrowing of the capillaries and seal blood vessels.

Epsilon-aminocaproic acid, as an inhibitor of fibrinolysis, ensures the stability of the formed clot, preventing its premature destruction by plasmin, and stabilizes the fibrin clot over a long period.

Example of getting a hemostatic. Taken fine powder of calcium alginate as the basis of hemostatic agents in a number of 73.5 g, is added 6 g of aminocaproic xtractive yarrow, horsetail, nettle, St. John's wort in 180 ml of 95% ethyl alcohol. The resulting mixture on a rotary evaporator at a temperature of 75-105oWith a residual pressure of up to 5 mm RT.article Argonauts water-alcohol mixture. The drying process should not exceed 4 hours. The resulting brown powder Packed in sealed packages of moisture-proof and light-proof material.

A series of works (selection of a new framework of the preparation, selection of components, the development of a framework process), which allows to significantly increase the hemostatic effect. When conducting a series of tests of hemostatic activity means the time of hemostasis was reduced by at least 30% compared with the norm (see table).

All components of the hemostatic agents are available and are produced in Russia. The technology for this hemostatic simple, does not require the use of toxic substances, is implemented in small areas and uses little pieces of equipment that significantly reduces the cost of the drug compared with domestic and foreign counterparts.

Sources of information 1. The prospectus of the company "Septodont, France, 1998

2. The prospectus of the company "Hemal", USA, 2000

3. Guidance on the use of blood and blood>6. The copyright certificate of the Russian Federation 725289 from 31.07.1975, prototype.

Claims

The hemostatic agent containing a powder base, characterized in that it also contains phyto-extracts and Epsilon-aminocaproic acid, and as the basis taken alginate calcium, with a ratio of components, wt.%:

Alginate calcium 50 - 80

Phytoextracts 15 - 30

Epsilon-aminocaproic acid 5 - 20

 

Same patents:

The invention relates to medicine, namely to urology
The invention relates to medicine
The invention relates to medicine and can be used in neurosurgery and neurotraumatology and surgery to stop capillary bleeding
The invention relates to medicine, namely to surgery, and can be used for hemostasis surface wounds parenchymatous organs

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used to freshen breath and as an aid in the treatment of inflammatory diseases of the oral cavity

The invention relates to medicine, in particular to the pharmaceutical industry, and can be used as an auxiliary bracing means with hypothermia, during the initial stages of colds, chronic inflammatory diseases of the bronchopulmonary system

The invention relates to pharmaceutical industry that manufactures drugs therapeutic and prophylactic purposes, and can be used for the prevention and auxiliary treatment of gastritis, duodenitis and colitis of various etiology

The invention relates to animal husbandry

The invention relates to the field of pharmacy (pharmacognosy)

The invention relates to the field of veterinary medicine

The invention relates to cosmetics

The invention relates to medicine and can be used in the practice of the therapeutic and preventive institutions for patients with Lyme borreliosis

The invention relates to medicine, in particular to plants with nephrolithiasis action, and can be used for the treatment and prevention of urolithiasis

The invention relates to medicine and can be used as a complex chemoradiation therapy for treatment and prevention of food-based dietary supplements containing activated natural antioxidants
The invention relates to medical, pharmaceutical and food industries

The invention relates to medicine, namely to traumatology and maxillofacial surgery, and for the treatment of fractures of the jaw

The invention relates to pharmaceutical industry

The invention relates to pharmaceutical industry

The invention relates to medicine, namely to the pharmaceutical industry
Up!